Trial Profile
A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Afatinib (Primary) ; Alectinib (Primary) ; Alpelisib (Primary) ; Atezolizumab (Primary) ; Axitinib (Primary) ; Bevacizumab (Primary) ; Cabozantinib (Primary) ; Cobimetinib (Primary) ; Crizotinib (Primary) ; Dabrafenib (Primary) ; Dacomitinib (Primary) ; Durvalumab (Primary) ; Entrectinib (Primary) ; Erdafitinib (Primary) ; Erlotinib (Primary) ; Ipilimumab (Primary) ; Lenvatinib (Primary) ; Lorlatinib (Primary) ; Nilotinib (Primary) ; Nivolumab (Primary) ; Olaparib (Primary) ; Palbociclib (Primary) ; Panitumumab (Primary) ; Pembrolizumab (Primary) ; Pertuzumab (Primary) ; Regorafenib (Primary) ; Ribociclib (Primary) ; Rucaparib (Primary) ; Sunitinib (Primary) ; Talazoparib (Primary) ; Trametinib (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary) ; Vemurafenib (Primary) ; Vismodegib (Primary)
- Indications Adrenal cancer; Advanced breast cancer; B-cell lymphoma; Biliary cancer; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Glioblastoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Salivary gland cancer; Sarcoma; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms DRUP
- 24 Oct 2023 Results (n=30) assessing safety and efficacy of crizotinib in METmut aNSCLC patients, presented at the 48th European Society for Medical Oncology Congress.
- 24 Oct 2023 Results (n=1019) assessing the impact of these protocol waivers on patient safety and treatment efficacy, presented at the 48th European Society for Medical Oncology Congress.
- 31 Aug 2023 Results from DRUP and Australian MoST , for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib published in the International Journal of Cancer